Market research
RHY.AU Rhythm Biosciences Limited
AU AUD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 23M
- P/E ratio
- Not available
- Analyst target
- 0.535
- Dividend yield
- Not available
- Beta
- 0.57
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- AU000000RHY2
- Market cap
- 23M
- P/E ratio
- Not available
- Analyst target
- 0.535
- Dividend yield
- Not available
- Beta
- 0.57
About
About Rhythm Biosciences Limited
Rhythm Biosciences Limited, a medical diagnostics company, develops and commercialises medical diagnostic tests for cancer detection in Australia and the United States. The company offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. Rhythm Biosciences Limited was incorporated in 2017 and is headquartered in Parkville, Australia.
Research context
Rhythm Biosciences Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the RHY.AU discussion.
5 years, 6 months ago
Rhythm Biosciences Limited is currently in a long term downtrend where the price is trading 8.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Rhythm Biosciences Limited's total revenue sank by 60.3% to $10K since the same quarter in the previous year.
Its net income has dropped by 5.0% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 51.0% to $-770K since the same quarter in the previous year.
Based on the above factors, Rhythm Biosciences Limited gets an overall score of 1/5.